Cumberland Pharmaceuticals (CPIX) Income towards Parent Company (2010 - 2026)

Cumberland Pharmaceuticals has reported Income towards Parent Company for 16 years, with the latest figure at -$3.1 million in Q1 2026.

• Quarterly Income towards Parent Company fell 351.64% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.2 million (down 119.88% YoY) and the FY2025 annual result came in at -$2.9 million, up 55.75% from the prior year.
• Income towards Parent Company eased to -$3.1 million in Q1 2026 per CPIX's latest filing, from -$1.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $1.2 million in Q1 2025 and troughed at -$6.3 million in Q4 2023.
• A 4-year average of -$1.4 million and a median of -$1.4 million in 2025 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company plunged 1204.25% in 2024, then surged 165.61% in 2025.
• Over 4 years, Income towards Parent Company stood at -$6.3 million in 2023, then soared by 69.82% to -$1.9 million in 2024, then climbed by 25.57% to -$1.4 million in 2025, then plunged by 121.91% to -$3.1 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$3.1 million, -$1.4 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.